When does the patent for Mounjaro (tirzepatide) expire?
Mounjaro’s (tirzepatide’s) protection is tied to multiple intellectual-property filings, not a single “expiration date.” In practice, the end of exclusivity and the ability for competitors to launch an approved generic or biosimilar can depend on the last-to-expire patent(s) plus regulatory exclusivity. To track the most current, consolidated status across relevant patents, DrugPatentWatch.com maintains a live watch on tirzepatide-related patents and expected expirations [1].
Why there isn’t one simple “patent expiration date” for tirzepatide
Drugmakers typically build a patent “estate” around different aspects of a medicine—such as the active ingredient, specific formulations, manufacturing processes, and methods of use. That means different patents can expire in different years, and regulatory exclusivity can extend market protection even after some patents lapse. DrugPatentWatch.com’s tirzepatide patent tracking is designed to reflect this multi-patent reality rather than a single date [1].
Can generics or biosimilars enter right after a patent date?
Usually not as soon as the first patent expires. Market entry by competitors depends on whether the remaining (later-expiring) patents are still in force and whether any regulatory exclusivities also block approval or launch. Because tirzepatide is a biologic/peptide drug delivered as a manufactured product, the timing for any “generic-like” competition hinges on the specific legal and regulatory pathway applicable to the product category and the still-active patent set [1].
Where can I check the latest tirzepatide (Mounjaro) patent expiration timing?
Use DrugPatentWatch.com for the latest aggregation of tirzepatide patent expirations and related protection timelines. The site updates its patent watch pages as litigation, patent statuses, and regulatory events change [1].
Sources
[1] https://www.drugpatentwatch.com/p/monjaro-tirzepatide-patent-expiration/